As of 2026-04-11, the Intrinsic Value of BioCryst Pharmaceuticals Inc (BCRX) is 23.55 USD. This BCRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 9.56 USD, the upside of BioCryst Pharmaceuticals Inc is 146.30%.
The range of the Intrinsic Value is 16.68 - 40.58 USD
Based on its market price of 9.56 USD and our intrinsic valuation, BioCryst Pharmaceuticals Inc (BCRX) is undervalued by 146.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 16.68 - 40.58 | 23.55 | 146.3% |
| DCF (Growth 10y) | 18.93 - 43.12 | 25.96 | 171.5% |
| DCF (EBITDA 5y) | 17.03 - 23.54 | 20.22 | 111.5% |
| DCF (EBITDA 10y) | 19.18 - 27.59 | 23.09 | 141.5% |
| Fair Value | 26.30 - 26.30 | 26.30 | 175.13% |
| P/E | 16.34 - 23.05 | 20.03 | 109.5% |
| EV/EBITDA | 15.73 - 25.20 | 20.67 | 116.3% |
| EPV | 1.52 - 2.73 | 2.12 | -77.8% |
| DDM - Stable | 7.83 - 23.74 | 15.78 | 65.1% |
| DDM - Multi | 8.95 - 21.98 | 12.82 | 34.1% |
| Market Cap (mil) | 2,397.65 |
| Beta | 0.63 |
| Outstanding shares (mil) | 250.80 |
| Enterprise Value (mil) | 2,776.35 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.70% |
| Cost of Debt | 4.25% |
| WACC | 8.75% |